Price Controls And Competitive Risks Will Challenge Cell Therapy Recovery

Key Takeaways

• Heightened competition, pricing pressures, and reimbursement scrutiny threaten revenue growth and limit predictability despite rising global demand for cell therapies.
  
• Heavy dependence on CARVYKTI and significant R&D spending expose Legend to concentration risk and continued margin pressures in a rapidly evolving treatment landscape.
  
• Heavy dependence on a single product, intensifying competition, regulatory and cost pressures, and ongoing investment needs threaten long-term growth, profitability, and revenue diversification.

Catalysts

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

• Although Legend Biotech is benefiting from the rapidly aging global population and rising cancer incidence, which should expand the patient base and increase demand for CAR-T therapies, the company still faces substantial risk from tightening price controls and reimbursement scrutiny in key markets like the US and Europe. These policy trends can directly compress average selling prices and cap revenue growth as new cost-containment measures are implemented.
  
• While the relaxation of REMS requirements and improved patient monitoring guidelines in the US are poised to enhance CARVYKTI access and uptake, the long-term commercial opportunity is still clouded by persistent threats of stricter reimbursement criteria and demands for affordability in public healthcare systems. This may limit broad patient access, causing uncertainty around future sales growth and predictability of earnings.
  
• Despite Legend's efforts to expand global manufacturing and distribution through partnerships and new facilities actions that would normally enhance margins and operational scale the company remains highly dependent on CARVYKTI. Heavy reliance on a single asset exposes Legend to concentration risk, meaning that any competitor advance in next-generation or off-the-shelf therapies could quickly erode both revenue and margin.
  
• Although ongoing clinical data and an expanding pipeline provide reasons for optimism around future product launches, realizing value from these assets will require ongoing high R&D and manufacturing investments. These costs may weigh on net margins and push out the timeline to consistent profitability, especially if approval timelines stretch or commercialization hurdles arise.
  
• While the field is buoyed by advances in cell therapy and more favorable regulatory pathways, Legend's autologous CAR-T approach could lose market share to innovative off-the-shelf modalities and bispecific antibodies, both of which target the same patient populations. This mounting competition risks diminishing the long-term relevance of Legend's current portfolio and could limit both revenue growth and operating leverage.

Legend Biotech Future Earnings and Revenue Growth

Assumptions

• This narrative explores a more pessimistic perspective on Legend Biotech compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Legend Biotech's revenue will grow by 37.4% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from -40.8% today to 12.2% in 3 years time.
• The bearish analysts expect earnings to reach $251.9 million (and earnings per share of $1.24) by about August 2028, up from $-325.3 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 48.8x on those 2028 earnings, up from -19.9x today. This future PE is greater than the current PE for the US Biotechs industry at 15.2x.
• Analysts expect the number of shares outstanding to grow by 0.61% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Legend Biotech Future Earnings Per Share Growth

Risks

• Intensifying competition from alternative modalities such as bispecific antibodies and off-the-shelf allogeneic cell therapies, which are being actively developed by partners like Johnson & Johnson as well as other industry players, could erode CARVYKTI's market share and diminish long-term revenue growth and pricing power.
  
• Legend Biotech's continued heavy reliance on CARVYKTI as its lead and primary commercial asset exposes it to significant product concentration risk, meaning that any regulatory setback, loss of competitive differentiation, or market saturation could lead to dramatic declines in company-wide revenues and earnings.
  
• Significant R&D and manufacturing investments will remain necessary to sustain clinical advances and global expansion, as alluded to by ongoing spending on new facilities and pipeline programs, which could suppress net margins and delay the company's achievement of sustainable profitability.
  
• Political and payer-driven pressure to control healthcare costs in major markets, notably the US and EU, could result in stricter reimbursement criteria and potential pricing cuts for high-cost cell therapies, reducing the visibility and reliability of future revenue streams.
  
• Regulatory or operational hurdles-such as the requirement for specialized site accreditation, infrastructure limits in community settings, and unpredictable enrollment timelines for pivotal studies in earlier-line or new indications-could slow the pace of expansion and delay revenue diversification, constraining medium
• to long-term earnings and revenue growth.

Valuation

• The assumed bearish price target for Legend Biotech is $54.0, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Legend Biotech's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $94.0, and the most bearish reporting a price target of just $54.0.
  
• In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $2.1 billion, earnings will come to $251.9 million, and it would be trading on a PE ratio of 48.8x, assuming you use a discount rate of 6.8%.
  
• Given the current share price of $35.08, the bearish analyst price target of $54.0 is 35.0% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.